Activating a collaborative innate-adaptive immune response to control metastasis.

[1]  S. Hannenhalli,et al.  Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis , 2021, Cell.

[2]  Sean C. Bendall,et al.  Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity , 2020, Nature Cancer.

[3]  Amy L. Olex,et al.  Regulatory T Cells Support Breast Cancer Progression by Opposing IFN-γ-Dependent Functional Reprogramming of Myeloid Cells. , 2020, Cell reports.

[4]  Wei Zhang,et al.  Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies , 2020, Cancer Immunology, Immunotherapy.

[5]  T. Doman,et al.  Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study , 2020, Clinical Cancer Research.

[6]  Elias A. Rahal,et al.  Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model , 2020, Frontiers in Oncology.

[7]  E. Song,et al.  DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25 , 2020, Nature.

[8]  I. Melero,et al.  Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. , 2019, Cancer cell.

[9]  Aditi Gupta,et al.  In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. , 2019, The Journal of clinical investigation.

[10]  F. Marincola,et al.  Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod , 2019, Scientific Reports.

[11]  J. Joyce,et al.  Re-education of macrophages as a therapeutic strategy in cancer. , 2019, Immunotherapy.

[12]  J. Varner,et al.  Targeting Tumor-Associated Macrophages in Cancer. , 2019, Trends in immunology.

[13]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[14]  Michael S. Goldberg,et al.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice , 2018, Science.

[15]  D. Fearon,et al.  Cancer cell CCR2 orchestrates suppression of the adaptive immune response , 2018, bioRxiv.

[16]  B. Vanderhyden,et al.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy , 2018, Cancers.

[17]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[18]  J. Pollard,et al.  A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.

[19]  W. Woodward,et al.  Inflammatory breast cancer biology: the tumour microenvironment is key , 2018, Nature Reviews Cancer.

[20]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.

[21]  N. Bercovici,et al.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.

[22]  T. Kitamura,et al.  Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors , 2018, Front. Cell Dev. Biol..

[23]  N. Carragher,et al.  Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer , 2018, Front. Immunol..

[24]  M. Croft,et al.  TNF activity and T cells. , 2018, Cytokine.

[25]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[26]  R. Müller,et al.  Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. , 2017, Trends in cancer.

[27]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, Journal for immunotherapy of cancer.

[28]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[29]  L. Chow,et al.  Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN , 2016, Clinical Cancer Research.

[30]  Wang Min,et al.  Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. , 2016, The Journal of clinical investigation.

[31]  I. McNeish,et al.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. , 2016, Cancer research.

[32]  Cheryl L. Sershen,et al.  Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages , 2016, PloS one.

[33]  M. Prados,et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.

[34]  P. Hertzog,et al.  Optimizing mouse models for precision cancer prevention , 2016, Nature Reviews Cancer.

[35]  D. Kaufman,et al.  Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. , 2016 .

[36]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[37]  L. Zitvogel,et al.  Autocrine signaling of type 1 interferons in successful anticancer chemotherapy , 2015, Oncoimmunology.

[38]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[39]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[40]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[41]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[42]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[43]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[44]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[45]  S. Demaria,et al.  Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer , 2012, Clinical Cancer Research.

[46]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[47]  Mikala Egeblad,et al.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.

[48]  K. Goa,et al.  Interferon Gamma-1b , 2012, Drugs.

[49]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[50]  D. Zamboni,et al.  A Method for Generation of Bone Marrow-Derived Macrophages from Cryopreserved Mouse Bone Marrow Cells , 2010, PloS one.

[51]  C. Figdor,et al.  Ovarian cancer creates a suppressive microenvironment to escape immune elimination. , 2010, Gynecologic oncology.

[52]  J. Zwaginga,et al.  Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential , 2010, Cancer Immunology, Immunotherapy.

[53]  S. Adams Toll-like receptor agonists in cancer therapy. , 2009, Immunotherapy.

[54]  M. Croft The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[55]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[56]  Chien-Fu Hung,et al.  Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer , 2008, Biologics : targets & therapy.

[57]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[58]  T. Herzog The current treatment of recurrent ovarian cancer , 2006, Current oncology reports.

[59]  K. Rock,et al.  Both Dendritic Cells and Macrophages Can Stimulate Naive CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells1 , 2005, The Journal of Immunology.

[60]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[61]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[62]  M. Kelm Nitric oxide metabolism and breakdown. , 1999, Biochimica et biophysica acta.

[63]  T. Parmely,et al.  An Interferon-γ-activated Site (GAS) Is Necessary for Full Expression of the Mouse iNOS Gene in Response to Interferon-γ and Lipopolysaccharide* , 1997, The Journal of Biological Chemistry.

[64]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[65]  D. Lopez,et al.  The altered tumoricidal capacity of macrophages isolated from tumor- bearing mice is related to reduce expression of the inducible nitric oxide synthase gene , 1996, The Journal of experimental medicine.

[66]  C. Nathan,et al.  Role of interferon regulatory factor 1 in induction of nitric oxide synthase , 1994, The Journal of experimental medicine.

[67]  C. Starnes,et al.  Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. , 1994, Pharmacology & therapeutics.

[68]  C. Nathan,et al.  Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide , 1993, The Journal of experimental medicine.

[69]  R. Rodriguiz,et al.  Recombinant human interferon gamma therapy for osteopetrosis. , 1992, The Journal of pediatrics.

[70]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.